v3.24.1.u1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue $ 54,592 $ 62,817
Total cost of revenue 32,817 35,745
Gross margin 21,775 27,072
Operating costs and expenses:    
Selling, general and administrative 38,304 33,241
Engineering and development 4,752 3,876
Total operating costs and expenses 43,056 37,117
Loss from operations (21,281) (10,045)
Other income (expense):    
Investment income 2,600 2,467
Interest expense (1,338) (1,509)
Other income, net 1,339 4,005
Total other income, net 2,601 4,963
Loss before provision for income taxes (18,680) (5,082)
Provision for income taxes (215) (492)
Net loss (18,895) (5,574)
Paid-in-kind dividend on Series C convertible preferred stock (2,000) (2,000)
Net loss attributable to common stockholders $ (20,895) $ (7,574)
Net loss per share - basic (in dollar per share) $ (0.43) $ (0.16)
Net loss per share - diluted (in dollar per share) $ (0.43) $ (0.16)
Weighted average shares outstanding - basic (in shares) 49,019,964 48,362,501
Weighted average shares outstanding - diluted (in shares) 49,019,964 48,362,501
Life Sciences Services    
Total revenue $ 36,786 $ 35,836
Total cost of revenue 21,602 19,076
Life Sciences Products    
Total revenue 17,806 26,981
Total cost of revenue $ 11,215 $ 16,669

Source

HTML PDF
ZIP